Germany's Merck KGaA has announced plans to cut jobs at it plant in Mollet, Spain, in an effort to improve productivity. The facility, which is located near Barcelona and is primarily used for the production of generics, currently operates at an efficiency level well below the European average. The firm, which runs the plant under an agreement with Mylan, which bought Merck's generics business, plans to add new production capacity once productivity rates have been successfully improved.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze